Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

Aref Al-Kali, Jorge Cortes, Stefan Faderl, Dan Jones, Caroline Abril, Sherry Pierce, Mark Brandt, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticle

23 Scopus citations

Fingerprint Dive into the research topics of 'Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences